Curadev Announces Licensing Agreement With Takeda for Novel STING Agonist

Wednesday, May 8, 2019 General News
Email Print This Page Comment bookmark
Font : A-A+

NEW DELHI and LONDON, May 8, 2019 /PRNewswire/ --

Curadev today announced it has licensed its novel lead small molecule Stimulator of Interferon Genes (STING) agonist (referred to by Curadev as CRD5500) and associated patents to Takeda Pharmaceutical Company Limited (Takeda). The financial terms were not disclosed.

     (Logo:

https://mma.prnewswire.com/media/883133/Curadev_Pharma_Logo.jpg )

"Our drug discovery efforts have targeted fundamental host immune mechanisms to stimulate anti-tumor immunity," said Curadev Co-Founder and Chief Scientific Officer Arjun Surya, Ph.D. "With its commitment to pursuing novel immuno-oncology targets, Takeda is an ideal partner to collaborate on the further development of a STING agonist that is potential first-in-class small molecule."

A poster presented at the 2019 Annual Meeting of the American Association for Cancer Research (LB-061: "CRD5500: a versatile small molecule STING agonist amenable to bioconjugation as an ADC") reported that the Curadev STING agonist potently activates all major known human STING variants and activates the immune system to shrink distant tumors and combines well with anti-PD-L1/anti-CTLA4/IDO-TDOi when dosed IT or systematically. It also demonstrated that the molecule has a long tumor residence time, good drug like properties, can be dosed by multiple routes, and has been successfully conjugated with trastuzumab.

"We look forward to collaborating with Curadev to further develop this novel STING agonist," said Chris Arendt, Head Oncology Drug Discovery Unit, Takeda. "This project is an example of Takeda's commitment to collaborating with world-class partners like Curadev to pursue novel immuno-oncology targets that may one day deliver transformational benefit to patients."

About Curadev 

Curadev is a drug discovery company that has created an IP portfolio from internal drug discovery programs. Since its labs were operational in 2011, Curadev has built a strong track record of out-licensing IP and collaboration with industry partners (Endo, Medivation, Roche & now Takeda) and established active research collaborations with reputed research institutes such as UTSW Medical Centre, Dallas and INSERM, Paris. 

For Curadev Partnering, contact: Manish Tandon Co-founder & CFO Curadev Pharma +91-120-4081818 manish@curadev.in  

http://www.curadev.in



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store